Sponsors (61)
Official title: To provide for research and education with respect to uterine fibroids, and for other purposes.
Introduced July 15, 2025 by Yvette Diane Clarke · Last progress July 15, 2025
The bill channels federal research, data collection, and targeted outreach to improve diagnosis, treatment options, and equity for women with uterine fibroids, but does so at measurable cost to taxpayers, with risks of administrative burden, funding trade‑offs, uneven implementation, and potential constraints on the range of treatment options discussed.
Women with uterine fibroids (and clinicians/researchers treating them) will receive increased and more predictable federal research funding over multiple years, likely accelerating development of better diagnostics, fertility‑preserving and minimally invasive treatments, and reducing long‑term complications.
Women—especially racial and ethnic minority women and Medicaid/CHIP beneficiaries—will gain expanded, targeted outreach and education about fibroid prevalence, risks, and non‑hysterectomy treatment options, improving awareness and earlier care‑seeking.
State and federal policymakers (and program administrators) will get better data on Medicaid/CHIP treatment frequency and spending for fibroids, enabling more informed policy, coverage decisions, and budget planning to improve access.
Taxpayers and the federal budget will face increased spending (including an estimated $150 million discretionary cost over five years plus additional authorized sums), raising fiscal costs and competing budgetary pressures.
Patients with other diseases, researchers, and health programs may be disadvantaged if federal research and program funds are shifted toward fibroid initiatives, potentially crowding out other NIH/AHRQ priorities under constrained budgets.
State governments and health care providers will incur additional administrative and reporting burdens (and related costs) to collect Medicaid/CHIP data and to adopt and disseminate guideline‑based materials and participate in outreach.
Based on analysis of 7 sections of legislative text.
Directs HHS/NIH to expand fibroid research, collect Medicaid/CHIP treatment data, run education campaigns, and promote evidence‑based care; authorizes multi‑year funding.
Expands federal attention to uterine fibroids by funding and coordinating research, collecting Medicaid/CHIP treatment data, producing public education, and promoting evidence-based clinical care—with new appropriations and reports to Congress. The bill targets gaps in knowledge, racial disparities, and non‑hysterectomy treatment awareness, and authorizes multi-year funding streams for research and outreach.